<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - BUPRENORPHINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>BUPRENORPHINE</h1>

        <p><a href="../drugClass/PHP34573.html">OPIOIDS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Moderate to severe pain</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200&#8211;400 micrograms every 6&#8211;8 hours.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                300&#8211;600 micrograms every 6&#8211;8 hours.</li>
              <li class="dose child"><strong>For children (body-weight 16&#8211;24 kg)</strong><br/>
                100 micrograms every 6&#8211;8 hours.</li>
              <li class="dose child"><strong>For children (body-weight 25&#8211;37.4 kg)</strong><br/>
                100&#8211;200 micrograms every 6&#8211;8 hours.</li>
              <li class="dose child"><strong>For children (body-weight 37.5&#8211;49 kg)</strong><br/>
                200&#8211;300 micrograms every 6&#8211;8 hours.</li>
              <li class="dose child"><strong>For children (body-weight 50 kg and above)</strong><br/>
                200&#8211;400 micrograms every 6&#8211;8 hours.</li>
              <li class="dose child"><strong>For children 6 months&#8211;11 years</strong><br/>
                3&#8211;6 micrograms/kg every 6&#8211;8 hours (max. per dose 9 micrograms/kg).</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                300&#8211;600 micrograms every 6&#8211;8 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Premedication</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 micrograms.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                300 micrograms.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Intra-operative analgesia</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300&#8211;450 micrograms.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunct in the treatment of opioid dependence</span>,
            </h4>
            <p class="specificity"><span class="route">By sublingual administration</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 0.8&#8211;4 mg for 1 dose on the first day, adjusted in steps of 2&#8211;4 mg daily if required; usual dose 12&#8211;24 mg daily; maximum 32 mg per day.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>For opioid substitution therapy, in patients taking methadone who want to switch to buprenorphine, the dose of methadone should be reduced to a maximum of 30&#8239;mg daily before starting buprenorphine treatment. If the dose of methadone is over 10&#8239;mg daily, buprenorphine can be started at a dose of 4&#8239;mg daily and titrated according to requirements; if the methadone dose is below 10&#8239;mg daily, Buprenorphine can be started at a dose of 2&#8239;mg daily.</p>
            </section>
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Buprenorphine is an opioid-receptor partial agonist (it has opioid agonist and antagonist properties).</p>
            </section>
      </section>



      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, agitation, anorexia, anxiety, asthenia, diarrhoea, dyspepsia, dyspnoea, fatigue, mild withdrawal symptoms in patients dependent on opioids, paraesthesia, vasodilatation,
              </p>
              <p>
                <strong>uncommon:</strong> Angina in adults, cough, depersonalisation, dry eye, dry skin, dysarthria, flatulence, hypertension, hypoaesthesia, hypoxia, impaired memory, influenza-like symptoms, muscle cramp, myalgia, pyrexia, restlessness, rhinitis, rigors, syncope, taste disturbance, tinnitus, tremor, wheezing,
              </p>
              <p>
                <strong>rare:</strong> Diverticulitis in children, dysphagia, impaired concentration, paralytic ileus, psychosis,
              </p>
              <p>
                <strong>veryRare:</strong> Hiccups, hyperventilation, muscle fasciculation, retching,
              </p>
              <p>
                <strong>notKnown:</strong> Hepatic necrosis, hepatitis,
              </p>
        
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">transdermal</ph> use in adults</h3>
                <p class="title">Fever or external heat</p>
              <p>Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat (may also increase absorption).</p>
            </section>
        
            <section class="overdosageInformation">
              <p> The effects of buprenorphine are only partially reversed by naloxone.</p>
            </section>
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">sublingual</ph> use in children</h3>
              <p>For administration by <i>mouth</i>, tablets may be halved.</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA114</h3>
              <p outputclass="specificity">In adults</p> <p outputclass="title">Methadone and buprenorphine for the management of opioid dependence (January 2007)</p> <p>Oral methadone and buprenorphine are recommended for maintenance therapy in the management of opioid dependence. Patients should be committed to a supportive care programme including a flexible dosing regimen administered under supervision for at least 3 months, until compliance is assured. Selection of methadone or buprenorphine should be made on a case-by-case basis, but methadone should be prescribed if both drugs are equally suitable.</p><xref format="html" href="http://www.nice.org.uk/TA114">www.nice.org.uk/TA114</xref>
                <a href="http://www.nice.org.uk/TA114" target="_blank">www.nice.org.uk/TA114</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Impaired consciousness
          </li>
        </ul>
        <ul>
          <li>
              <strong>With transdermal use:</strong>
            other opioids should not be administered within 24 hours of patch removal (long duration of action) in adults
          </li>
        </ul>
        <ul>
          <li>
              <strong>When used for adjunct in the treatment of opioid dependence:</strong>
            hepatitis B infection in adults
          </li>
          <li>
              <strong>When used for adjunct in the treatment of opioid dependence:</strong>
            hepatitis C infection in adults
          </li>
          <li>
              <strong>When used for adjunct in the treatment of opioid dependence:</strong>
            pre-existing liver enzyme abnormalities in adults
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor liver function; when used in opioid dependence baseline liver function test is recommended before commencing therapy, and regular liver function tests should be performed throughout treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">sublingual</ph> use in children</h3>
              <p>Sublingual tablets not licensed for use in children under 6 years.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>Injection not licensed for use in children under 6 months.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">transdermal</ph> use in adults</h3>
              <p>Transdermal buprenorphine patches are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose.</p>
            </section>
      </section>




      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
              <p>Documentation of viral hepatitis status is recommended before commencing therapy for opioid dependence.</p>
            </section>
      </section>





      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of BUPRENORPHINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77224"><a href="../medicinalForm/PHP77224.html" data-target="#PHP77224" data-action="load">Sublingual tablet</a></div>
            <div id="PHP77232"><a href="../medicinalForm/PHP77232.html" data-target="#PHP77232" data-action="load">Solution for injection</a></div>
            <div id="PHP77239"><a href="../medicinalForm/PHP77239.html" data-target="#PHP77239" data-action="load">Transdermal patch</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
